Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Dehaier restructures to focus on wearables
China’s Dehaier Medical Systems said that it plans to ditch its unprofitable medical device businesses so it can focus on its wearable sleep respiratory business.
Dehaier said it plans to form a new subsidiary called Connection Wearable Health Technology by the end of this month, aiming to focus on “wearable sleep respiratory and mobile health related businesses.” Read more
2. Secondary offering could drum up $1.1B for Zimmer Biomet shareholders
Zimmer Biomet said that an 11 million-share secondary offering by some of its shareholders could drum up nearly $1.1 billion.
The Warsaw, Ind.-based orthopedics titan said affiliates of hedge fund Blackstone and investment bank Goldman Sachs are selling shares at $96.45 apiece. ZBH shares slid -1.6% to $95.99 apiece in pre-market trading today, after posting a $97.51 close yesterday. Read more
1. FDA approves Medtronic’s Amplia, Compia MRI-safe CRT-Ds
Medtronic claimed title to being to only company with cardiac resynchronization therapy defibrillators approved by the FDA for MRI scans.
The Fridley, Minn.-based medical device giant said the FDA approved its Amplia and Compia MRI Quad CRT-D SureScan devices for MRI scans on any part of the body without positioning restrictions. Medtronic plans to have the heart failure devices on the market “in the coming months,” according to a press release. Read more
